VectorB2B
VectorB2B is a Lisbon-based full-service Contract Research Organisation (CoLAB) providing integrated drug development services — from discovery and GLP toxicology through GMP manufacturing to Phase I–IV clinical trials — for biotech and pharma sponsors across Europe.
- Company typePrivate
- Founded2019
- HeadquartersLisboa, Portugal
- Headcount11–50
- GTM typeB2B
- OfferingServices
What VectorB2B does
VectorB2B – Drug Developing – Association for Research in Biotechnology is a Lisbon-headquartered, privately constituted Portuguese association (CoLAB) operating as a full-service Contract Research Organisation (CRO). It serves biotechnology and pharmaceutical companies requiring integrated drug development support from preclinical discovery through clinical trials Phase I–IV, as well as Portuguese hospital investigation centres needing embedded study coordination and regulatory support. Its service portfolio covers discovery, GLP/non-GLP toxicology, GMP-certified chemistry manufacturing and controls (with particular strength in biologic medicines and phage therapies), full-service clinical trial management, functional service providing (FSP) for hospitals, R&D portfolio management consulting, and integrated solutions spanning medical devices, animal health, cosmetics, cannabis, and food supplements. The company holds the only GLP-certified in vivo toxicology facility in Portugal and operates a GMP-certified manufacturing plant for Investigational Medicinal Products.
Underlying the service offering is a proprietary clinical trial technology suite (eSuite) comprising CTMS, RTSM, eTMF, EDC, ePRO/eCOA, eConsent, and wearables/device integration, complemented by specialised preclinical platforms including in vivo phage display (via member FASLAB), drug immunogenicity assessment using FO-SPR and cell-based NAb assays, cell-derived and patient-derived xenograft models, and in vivo retinal disease research models. The business model is fee-for-service and managed-service contracts with biotech and pharma sponsors, supplemented by FSP agreements with Portuguese hospital units (ULS Coimbra, ULS da Lezíria, ULS Loures-Odivelas). Pricing is not publicly disclosed but is positioned as cost-competitive and fixed-budget, leveraging Portugal's cost base relative to Western Europe and the US. Go-to-market is consultative and relationship-driven — direct enterprise engagement with R&D teams, conference participation (PEGS Europe, BIOSPAIN, ATMP Summit, EATRIS events), consortium membership (5 named consortia including CoroPrevention, LiverTarget, Bio-Hub, PRR, Mission Interface), and EIC Service Catalogue positioning targeting EU-funded early-stage developers. The company is co-led by Co-CEOs Ana Custódio and Francisco Castro and lists over 50 client and partner organisations including MSD, Labcorp, Eurofins, SGS, Technophage, Atreca, Fundação Champalimaud, and AICIB.
VectorB2B firmographics
Firmographics- Name
- VectorB2B
- Legal name
- VectorB2B – Drug Developing – Association for Research in Biotechnology
- Website
- https://vectorb2b.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VectorB2B is a Lisbon-based full-service Contract Research Organisation (CoLAB) providing integrated drug development services — from discovery and GLP toxicology through GMP manufacturing to Phase I–IV clinical trials — for biotech and pharma sponsors across Europe.
- Ownership category
- akta.pro rank
VectorB2B industry classification
Industry- Product category
- Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)
Keywords
Where VectorB2B is headquartered
LocationHeadquarters
- HQ city
- Lisboa
- HQ country
- Portugal
- HQ region
- Europe
Offices1 record
Markets served
VectorB2B business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- CRO Preclinical Services: Fee-for-service preclinical research contracts encompassing discovery, GLP toxicology studies, bioanalysis, and pharmacology studies conducted at the Portugal-based facility. Revenue is generated on a per-study or fixed-budget basis.
- GMP Manufacturing Services: Manufacturing of biologic medicines and Investigational Medicinal Products (IMPs) for clinical trial supply, GMP-certified, with particular strength in phage therapies. Revenue generated through manufacturing contracts with biotech and pharma sponsors.
- Clinical Trial Management Services: Full-service CRO support across phases I–IV, encompassing project management, monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory affairs, and site coordination. Billed through study contracts with pharmaceutical and biotech sponsors.
- Functional Service Providing (FSP): Dedicated study coordinators and operational support for hospital investigation centres, including site feasibility, patient recruitment oversight, CRF data management, regulatory and contract management, and grant management. Revenue through service agreements with hospitals and clinical research sites.
- R&D Portfolio Management Consulting: Strategic consulting for R&D portfolio optimisation, including reformulation, repurposing, new product development and go-to-market strategy for drug development programmes.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
VectorB2B product offering
Product offeringCore offering
VectorB2B is a Contract Research Organization (CRO) structured as a Portuguese CoLAB (collaborative laboratory) that provides integrated drug development services to pharmaceutical and biotechnology clients. Its offerings span discovery, GLP-certified toxicology, GMP-certified chemistry manufacturing, clinical services, functional service providing, R&D portfolio management, and end-to-end integrated solutions across the development lifecycle.
Product overview
VectorB2B is a full-service Contract Research Organization (CRO) providing integrated drug development services from bench to bedside. The company offers a comprehensive portfolio of services including Discovery, GLP/Non-GLP Toxicology (the only GLP-certified in vivo facility in Portugal), GMP-certified Chemistry Manufacturing (specializing in biologics and phage therapies), full Clinical Services (Phase I-IV), Functional Service Providing for hospital research centers, R&D Portfolio Management, and Integrated Solutions spanning medical devices, human health, animal health, cosmetics, cannabis, and food supplements. Supporting these services is a proprietary Technology Suite including CTMS, RTSM, eTMF, EDC, ePRO/eCOA, and eConsent platforms.
Differentiator
Problem solved
Functional benefit
Products and services
- Discovery Services Early-stage drug discovery research services supporting pharmaceutical and biotechnology sponsors in identifying and advancing candidate molecules.
- Toxicology Services GLP-certified toxicology studies conducted to regulatory standards to support drug development and safety assessment programs.
- Chemistry Manufacturing Services GMP-certified chemistry manufacturing services for drug substances and related chemical work supporting pharmaceutical development programs.
- Clinical Services Clinical research services supporting the execution of clinical trials as part of integrated drug development programs.
- Functional Service Providing (FSP) Functional service provision model offering dedicated resourcing and operational support for client R&D functions across the drug development lifecycle.
- R&D Portfolio Management Strategic management of client R&D portfolios, providing oversight and coordination of multi-program development activities.
- Integrated Solutions End-to-end integrated drug development solutions that combine discovery, preclinical, manufacturing, and clinical services into a single coordinated program for sponsors.
Quantifiable outcome
- Only in vivo TOX GLP-certified facility in Portugal
- +1 more outcomes
Companies that use VectorB2B
Customer profileNamed customers11 records
Segments5 records
Ideal customer profiles1 record
VectorB2B technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
VectorB2B partnerships and signals
Strategic signalPartnerships
22 partnerships are on record, tiered core and minor.
- AICIBcoreAICIB (Associção para Investigação e Inovação em Biomedicina) is listed as a client and partner, representing a national biomedical research association that collaborates with VectorB2B on drug development programmes.
- EATRIScoreEATRIS (European Research Infrastructure for Translational Medicine) is a key partner, with VectorB2B co-hosting the EATRIS Spotlight Programme Portugal workshop on transition from preclinical to clinical trials in May 2025.
- ULS CoimbracoreULS Coimbra (Unidade Local de Saúde de Coimbra) is a clinical partner, collaborating with VectorB2B and IdiPAZ to co-host the EATRIS Spotlight Programme workshop in 2025.
- ULS da LezíriacoreULS da Lezíria is a co-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), alongside Escola Superior de Saúde de Santarém and RISE Health.
- ULS Loures-OdivelascoreULS Loures-Odivelas is a key clinical research partner, with its coordinator Susana Saraiva publicly endorsing VectorB2B's clinical trial outsourcing services as critical to expanding the unit's research productivity.
- Escola Superior de Saúde de SantarémcoreCo-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), focused on strengthening clinical research ecosystems through structured dialogue.
- RISE HealthcoreCo-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), bringing institutional experience from multiple ULS units to the programme.
- SmartBio AnalyticscoreStrategic partnership aimed at identifying and referring clients who can benefit from VectorB2B's integrated drug development services and SmartBio Analytics' bioanalytical expertise. Partners will jointly explore new business opportunities by scouting companies and institutions with early-stage development projects and actively collaborate on research projects leveraging complementary capabilities.
- LabfitminorCollaboration with Labfit to advance research, strengthening joint commitment to meeting the evolving needs of the research community and critical projects in health innovation.
- ISEG Executive EducationminorVectorB2B partners with ISEG Executive Education in the Postgraduate Programme in Healthcare & Well-Being Management, combining academic expertise with real-world management challenges to equip healthcare professionals.
- FASLABcoreFASLAB is a member of the VectorB2B association contributing the in vivo phage display platform for antibody selection and targeted drug development. Applications in neurological diseases (blood-brain barrier crossing) and oncology.
- AktheliaminorListed as a client/partner with an interest in VectorB2B's integrated drug development services.
- AtrecaminorListed as a client and partner, representing a biotechnology company engaged with VectorB2B's CRO services.
- Fundação ChampalimaudcoreListed as a client and partner, representing a leading Portuguese biomedical research foundation with active collaboration interests in drug development.
- Gate2BrainminorListed as a client and partner, representing a biotech company developing brain-delivery technologies with potential collaboration on drug development.
- Health-Cluster-PortugalcoreListed as a client and partner, representing Portugal's national health innovation cluster, of which VectorB2B is an active member.
- P-BiominorListed as a client and partner, representing Portugal's pharmaceutical and biotechnology industry association.
- CoroPrevention ConsortiumcoreVectorB2B participates in the CoroPrevention research consortium focused on cardiovascular prevention, supporting drug development activities within the consortium framework.
- LiverTarget ConsortiumcoreVectorB2B participates in the LiverTarget research consortium focused on liver disease therapeutics, supporting drug development within the consortium.
- Bio-Hub ConsortiumcoreVectorB2B participates in the Bio-Hub consortium, a Portuguese initiative supporting biotechnology and life sciences innovation.
- Portuguese Recovery and Resilience Plan (PRR)coreVectorB2B participates in the Portuguese Recovery and Resilience Plan (PRR) as part of the national innovation ecosystem, with funding and structural support for health R&D activities.
- Mission Interface ProgrammecoreVectorB2B participates in the Mission Interface programme, a Portuguese initiative bridging research institutions and industry to accelerate technology transfer and innovation.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
VectorB2B competitors and assessment
Company assessmentRegional players
- Hovione: Portugal-based CDMO with global operations, specializing in drug substance and particle engineering. Hovione is the most prominent Portuguese contract pharmaceutical services peer, anchoring the same national innovation ecosystem as VectorB2B and serving overlapping biotech clients.
Direct peers
- SGS: Global testing, inspection, and certification company with significant life sciences and clinical research services. Listed as a client/partner on VectorB2B's website. SGS provides preclinical toxicology, bioanalytical, and clinical CRO services that overlap with VectorB2B's full-service offering.
- Eurofins Scientific: Global CRO and bioanalytical testing services provider listed as a client/partner on VectorB2B's website. Eurofins operates across pharmaceutical discovery, preclinical, and central laboratory services, directly overlapping with VectorB2B's GLP toxicology, bioanalysis, and clinical trial testing offerings.
- Charles River Laboratories: Major preclinical CRO with deep expertise in GLP toxicology, in vivo research models, and discovery services — directly comparable to VectorB2B's preclinical and toxicology core. Operates at global scale versus VectorB2B's Portugal-centric delivery.
- Pharmaron: Global CRO/CDMO offering integrated drug discovery, preclinical toxicology, CMC, and clinical services. Highly comparable to VectorB2B's integrated one-stop-shop model, with deeper geographic reach and scale.
- ICON plc: Global clinical CRO providing full-service clinical trial management, biostatistics, data management, and pharmacovigilance across Phase I-IV. Directly comparable to VectorB2B's clinical services offering and eSuite technology stack.
- Labcorp: Major global CRO (formerly Covance) offering preclinical toxicology, central labs, and clinical trial services. Listed as a client/partner on VectorB2B's website. Labcorp directly competes in VectorB2B's core GLP toxicology and clinical CRO categories, though at vastly larger scale.
Broad incumbents
- IQVIA: World's largest CRO and healthcare data analytics provider. Offers comprehensive clinical, commercial, and real-world evidence services. Functions as a broad incumbent versus VectorB2B's boutique full-service model, competing for biotech sponsor mandates.
- Syneos Health: Global biopharmaceutical solutions organization offering clinical CRO and commercial services. Comparable as a broad incumbent clinical CRO competing with VectorB2B for Phase I-IV biotech mandates.
Emerging players
- QPS Holdings: Mid-sized global CRO with strong preclinical toxicology, bioanalysis, and translational medicine capabilities. Comparable to VectorB2B in service breadth and therapeutic-area focus (notably neuroscience and ophthalmology), though with broader geographic reach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VectorB2B social profiles
Digital presenceVectorB2B compliance and trust
Trust signalCompliance2 records
VectorB2B financial estimates
Financial estimateRevenue estimate
Valuation estimate
VectorB2B leadership team
Management profileNumber of profiles
Profiles2 records
VectorB2B funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VectorB2B M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VectorB2B
What does VectorB2B do?
VectorB2B is a Contract Research Organization (CRO) structured as a Portuguese CoLAB (collaborative laboratory) that provides integrated drug development services to pharmaceutical and biotechnology clients. Its offerings span discovery, GLP-certified toxicology, GMP-certified chemistry manufacturing, clinical services, functional service providing, R&D portfolio management, and end-to-end integrated solutions across the development lifecycle.
Is VectorB2B a public or private company?
VectorB2B is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was VectorB2B founded?
VectorB2B was founded in 2019. It employs 11 to 50 people.
Where is VectorB2B based?
VectorB2B is headquartered in Lisboa, Portugal, in the Europe region.
How does VectorB2B make money?
Five revenue lines are on record. CRO Preclinical Services are the primary driver. The others are GMP Manufacturing Services, clinical Trial Management Services, functional Service Providing (FSP) and R&D Portfolio Management Consulting.
Who are VectorB2B's main competitors?
Hovione is listed as a regional player. Direct peers are SGS, Eurofins Scientific, Charles River Laboratories, Pharmaron, ICON plc and Labcorp. Broad incumbents are IQVIA and Syneos Health. QPS Holdings is listed as an emerging player.
Does VectorB2B have an API?
No public API is recorded for VectorB2B.
What industry is VectorB2B in?
VectorB2B's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 5417 and its SIC code is 8731.